I believe they acquired them for the glycoporronium/fomoterol asset which is the first combination drug for COPD which has a long acting bronchodilator and long acting muscarinic agent. In my opinion its not anywhere near as exciting as inhaled nadolol. Pearls asset is for prevention of symptoms of COPD as opposed to promotion of lung healing, which in my opinion is extremely important and will have a place in COPD guidelines eventually.
Oral nadolol for smoking cessation will work particularly for those patients with chronic bronchitis and COPD, so there is a big market there in my opinion, probably in conjunction with NRT to deal with cravings.
2016 should be an exciting year for Invion as long as the cash doesn't run out
IVX Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)